The stock of Quidel Corporation (NASDAQ:QDEL) is a huge mover today! The stock increased 5.74% or $1.2 during the last trading session, hitting $22.09. About 188,138 shares traded hands or 69.14% up from the average. Quidel Corporation (NASDAQ:QDEL) has risen 26.53% since February 26, 2016 and is uptrending. It has outperformed by 16.10% the S&P500.
The move comes after 7 months positive chart setup for the $682.23 million company. It was reported on Sep, 30 by Barchart.com. We have $29.38 PT which if reached, will make NASDAQ:QDEL worth $225.14 million more.
Analysts await Quidel Corporation (NASDAQ:QDEL) to report earnings on October, 26. They expect $-0.03 earnings per share, down 200.00% or $0.06 from last year’s $0.03 per share. After $-0.15 actual earnings per share reported by Quidel Corporation for the previous quarter, Wall Street now forecasts -80.00% EPS growth.
Quidel Corporation (NASDAQ:QDEL) Ratings Coverage
Out of 4 analysts covering Quidel (NASDAQ:QDEL), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Quidel has been the topic of 10 analyst reports since September 2, 2015 according to StockzIntelligence Inc. Barclays Capital initiated the shares of QDEL in a report on Wednesday, September 2 with “Overweight” rating. As per Friday, October 23, the company rating was downgraded by Craig Hallum. The firm earned “Hold” rating on Tuesday, February 9 by Canaccord Genuity. The stock of Quidel Corporation (NASDAQ:QDEL) has “Mkt Perform” rating given on Monday, December 14 by Raymond James. Raymond James upgraded the stock to “Outperform” rating in Monday, June 13 report. Canaccord Genuity maintained the shares of QDEL in a report on Friday, January 8 with “Buy” rating.
According to Zacks Investment Research, “Quidel Corp. discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women’s health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis.”
Insitutional Activity: The institutional sentiment decreased to 0.81 in Q2 2016. Its down 0.43, from 1.24 in 2016Q1. The ratio turned negative, as 8 funds sold all Quidel Corporation shares owned while 34 reduced positions. 5 funds bought stakes while 29 increased positions. They now own 30.18 million shares or 0.20% less from 30.24 million shares in 2016Q1.
Manufacturers Life Insur Company The accumulated 0% or 19,216 shares. Voya Invest Limited Liability Corporation has invested 0% of its portfolio in Quidel Corporation (NASDAQ:QDEL). The Maryland-based Brown Management Limited Liability Company has invested 1.62% in Quidel Corporation (NASDAQ:QDEL). Millennium Mgmt Ltd accumulated 186,992 shares or 0.01% of the stock. Citigroup has 0% invested in the company for 2,406 shares. Vanguard Gp Inc accumulated 1.96M shares or 0% of the stock. The Germany-based Deutsche Retail Bank Ag has invested 0% in Quidel Corporation (NASDAQ:QDEL). Northern Trust has invested 0% of its portfolio in Quidel Corporation (NASDAQ:QDEL). The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Quidel Corporation (NASDAQ:QDEL). D E Shaw Inc holds 0.01% of its portfolio in Quidel Corporation (NASDAQ:QDEL) for 432,415 shares. Fred Alger Mngmt last reported 0.06% of its portfolio in the stock. New York State Common Retirement Fund, a New York-based fund reported 890,655 shares. Sg Americas Ltd Liability Corporation has 0% invested in the company for 34,465 shares. Pitcairn Communication accumulated 17,593 shares or 0.04% of the stock. Blackrock Investment Limited Co has 100,748 shares for 0% of their US portfolio.
Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 3 selling transactions for $721,440 net activity. Another trade for 22,057 shares valued at $498,012 was sold by Bujarski Robert Joseph. Shares for $62,304 were sold by BRYANT DOUGLAS C. Another trade for 7,000 shares valued at $161,124 was made by TAMERIUS JOHN on Monday, August 1.
More important recent Quidel Corporation (NASDAQ:QDEL) news were published by: Streetinsider.com which released: “Quidel Corp (QDEL) Announces FDA Clearance for Its Solana Influenza A+B Assay” on September 27, 2016, also Seekingalpha.com published article titled: “Quidel Corporation’s (QDEL) CEO Doug Bryant on Q2 2016 Results – Earnings Call …”, Streetinsider.com published: “Quidel Corp (QDEL) Reports FDA Clearance for Solana Trichomonas Assay” on August 17, 2016. More interesting news about Quidel Corporation (NASDAQ:QDEL) was released by: Seekingalpha.com and their article: “Quidel: Getting Ready For The Flu Season” with publication date: August 16, 2016.
QDEL Company Profile
Quidel Corporation, incorporated on July 14, 1987, is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. The Firm sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. The Company’s diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including infectious diseases, women’s health, autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.